AltruBio is dedicated to developing innovative therapies that target specific pathways to improve the treatment of autoimmune and inflammatory diseases.
AltruBio is dedicated to developing innovative therapies that target specific pathways to improve the treatment of autoimmune and inflammatory diseases.
What Is ALTB-268
ALTB-268 is an engineered antibody that helps regulate the immune system by activating a receptor called PSGL-1. When the immune system is imbalanced, certain T-cells (white blood cells that help the immune system protect the body from disease) can become overactive. ALTB-268 regulates these cells by inhibiting their function, which helps restore balance to the immune system.
ALTB-268 works in a similar way to AltruBio’s first-generation antibody, ALTB-168. ALTB-168 has shown promise in treating various conditions, including ulcerative colitis, psoriasis, psoriatic arthritis, and graft-versus-host disease (GVHD). A recent study of ALTB-268 in healthy volunteers found that the drug was safe and well-tolerated without any serious side effects.
In November 2023, AltruBio began a new clinical study to evaluate the effectiveness of ALTB-268 in treating patients with ulcerative colitis that were unresponsive to prior biologic treatments.
Is Ulcerative Colitis Limiting Your Daily Living?
WE ARE LOOKING FOR PEOPLE DIAGNOSED WITH ULCERATIVE COLITIS TO PARTICIPATE IN A CLINICAL RESEARCH STUDY TO INVESTIGATE A POSSIBLE NEW TREATMENT
You may qualify if you:
• Have been diagnosed with moderately to severely active ulcerative colitis
• Have tried and failed at least one biologic treatment
• Are currently experiencing symptoms of ulcerative colitis
Consider participating in a clinical research trial for a chance to improve treatment options for yourself and others with poorly managed ulcerative colitis.
Choosing to participate in a clinical research trial is an important decision. The information obtained from the research study may help in the treatment of future patients with moderately to severely active ulcerative colitis and will provide important information about how well people respond to the study drug being investigated.
Clinical trials are highly regulated to ensure the safety and protection of participants’ rights.
Your doctor can explain the study information, safety considerations, and your rights in further detail.
For more information on the study, including contact details for participating trial sites in your area, click on the link below and search for Contacts and Locations
CLINTRIALS.GOV
AltruBio
top